Evaluation of the GenoScreen Deeplex Myc-TB workflow for drug-resistant tuberculosis testing in South Africa
Frontiers in Public Health · 07.07.2026 · 14
DOI: 10.3389/fpubh.2026.1834699 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Frontiers in Public Health, online erschienen am 07.07.2026. Verfasst von Jennifer Williams und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department o…. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Mycobacterium tuberculosis, Workflow, High-Throughput Nucleotide Sequencing. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Tuberculosis (TB) remains a leading cause of death globally, particularly in low- and middle-income countries, where healthcare systems are under-resourced and the burden of drug-resistant disease is highest. We assessed the feasibility of future integration of the GenoScreen Deeplex Myc-TB assay - a targeted next-generation sequencing (tNGS) assay for Mycobacterium tuberculosis detection and drug-resistance profiling within a national reference laboratory in South Africa. Rather than reporting routine implementation with patient testing in parallel to standard care, this study evaluated pre-implementation readiness through workflow optimisation, infrastructure preparation, staff training, and troubleshooting across the sequencing pathway. The main challenges identified were DNA extraction from complex specimens, targeted PCR quality control, manual library preparation, sequencing consistency, proprietary analysis software, and procurement and cost constraints. Overall, these findings show that the Deeplex Myc-TB assay has potential to complement routine diagnostic testing in high-burden settings, but that sustained adoption will require appropriate extraction methods, additional local quality control measures, reliable procurement pathways, recognised reporting, and longer-term investment in laboratory and data systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Molecular Biology and Human Genetics, SAMRC Centre for TB Research, DSI-NRF Centre of Excellence for Biomedical TB Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stelle…
- Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, United States.
- National Health Laboratory Service, Green Point Tuberculosis Laboratory, Cape Town, South Africa.
- Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Förderung
- NIAID NIH HHS
Zitieren
APA
Williams, J., Steyn, J., Grobbelaar, M., Naufal, F., Ghebrekristos, Y., Ismail, N., Limberis, J., Opperman, C., Singh, S., Venter, R., Mann, B. C., Hunter, F. B., Nalyvayko, A., Theron, G., Warren, R. M., & Metcalfe, J. Z. (2026). Evaluation of the GenoScreen Deeplex Myc-TB workflow for drug-resistant tuberculosis testing in South Africa. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1834699
Vancouver
Williams J, Steyn J, Grobbelaar M, Naufal F, Ghebrekristos Y, Ismail N, et al. Evaluation of the GenoScreen Deeplex Myc-TB workflow for drug-resistant tuberculosis testing in South Africa. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1834699
BibTeX
@article{Williams2026,
author = {Williams, Jennifer and Steyn, Janré and Grobbelaar, Melanie and Naufal, Fahd and Ghebrekristos, Yonas and Ismail, Nabila and Limberis, Jason and Opperman, Christoffel and Singh, Sarishna and Venter, Rouxjeane and Mann, Brendon C and Hunter, Felicia B and Nalyvayko, Alina and Theron, Grant and Warren, Robin M and Metcalfe, John Z},
title = {Evaluation of the GenoScreen Deeplex Myc-TB workflow for drug-resistant tuberculosis testing in South Africa},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1834699}
}
EUVIMED